MNLO: Menlo Therapeutics Inc. - Summary | Jitta

Menlo Therapeutics Inc.

NASDAQ:MNLO

Notice
Stock data is unavailable or the company’s delisted.
Price
$3.55
Loss Chance
58.0%
1.48JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
Sorry, the data is not yet available for this stock.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (66)
Recent Business Performance (15)
Financial Strength (0)
Return to Shareholders (0)
Competitive Advantage (9)
Jitta Signs
Recent Business PerformanceEarning Growth Last Year
Recent IPOLess than 3 years
CapExVery High
Key Stats
Jitta Score
Jitta Line
1.48
100.00%
3.03
208.13%
3.05
162.56%
Pharmaceuticals
4.53
678.08%
0.61
100.00%
6.36
51.23%
COMPANY DESCRIPTION
As of March 9, 2020, Menlo Therapeutics Inc. was acquired by Foamix Pharmaceuticals Ltd., in a reverse merger transaction. Menlo Therapeutics Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of serlopitant for the treatment of pruritus associated with dermatologic conditions in the United States. The company has completed Phase II clinical trials in pruritus associated with prurigo nodularis; psoriasis; chronic pruritus; atopic dermatitis; and refractory chronic cough. The company was formerly known as Tigercat Pharma, Inc. and changed its name to Menlo Therapeutics Inc. in May 2016. Menlo Therapeutics Inc. was founded in 2011 and is headquartered in Redwood City, California.